Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ET0038 in Advanced Solid Tumors
NCT05525559Phase 1Unknown
- Sponsor
- ETERN Therapeutics
- Start
- Nov 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ET0038 in solid tumor, sponsored by ETERN Therapeutics. Primary endpoints: Maximum Tolerated Dose at 2 years, Recommended Phase 2 Dose at 2 years and 1 more. Status: unknown.
02
Drugs
ET0038
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05525559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05525559.